Synonym
BQU57; BQU 57; BQU-57.
IUPAC/Chemical Name
6-amino-1,3-dimethyl-4-(4-(trifluoromethyl)phenyl)-1,4-dihydropyrano[2,3-c]pyrazole-5-carbonitrile
InChi Key
IJCMHHSFXFMZAI-UHFFFAOYSA-N
InChi Code
InChI=1S/C16H13F3N4O/c1-8-12-13(9-3-5-10(6-4-9)16(17,18)19)11(7-20)14(21)24-15(12)23(2)22-8/h3-6,13H,21H2,1-2H3
SMILES Code
CC1=NN(C2=C1C(C3=CC=C(C=C3)C(F)(F)F)C(C#N)=C(N)O2)C
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO, not in water
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Biological target:
BQU57 is a GTPase Ral inhibitor with IC50s of 2.0 μM in H2122 and 1.3 μM in H358.
In vitro activity:
Whether BQU57 could improve efficacy of a standard chemotherapeutic agent used to treat TNBC (triple negative breast cancer) was evaluated. MDA-MB-231 cells were treated with 100μM of BQU57 and a range of paclitaxel up to 1000nM. BQU57 had a significant additive effect with submaximal concentrations of paclitaxel (Fig. 6g).
Reference: Breast Cancer Res. 2021 Jun 12;23(1):65. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8196523/
In vivo activity:
The efficacy of BQU57 was tested in vivo by treatment of mice bearing palpable MDA-MB-231 tumors. BQU57 significantly hindered both primary tumor growth (Fig. 6d) and spontaneous lung metastasis as defined by the percent area of lung occupied by metastatic lesions (Fig. 6e). BQU57 was also tested in mice bearing patient-derived xenografts (PDX) derived from a TNBC lung metastasis. Again BQU57 significantly reduced tumor growth (Fig. 6f).
Reference: Breast Cancer Res. 2021 Jun 12;23(1):65. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8196523/
|
Solvent |
mg/mL |
mM |
| Solubility |
| DMF |
30.0 |
89.74 |
| DMSO |
65.3 |
195.42 |
| DMSO:PBS (pH 7.2) (1:2) |
0.3 |
0.99 |
| Ethanol |
12.5 |
37.39 |
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.
Preparing Stock Solutions
The following data is based on the
product
molecular weight
334.30
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
Formulation protocol:
1. Thies KA, Cole MW, Schafer RE, Spehar JM, Richardson DS, Steck SA, Das M, Lian AW, Ray A, Shakya R, Knoblaugh SE, Timmers CD, Ostrowski MC, Chakravarti A, Sizemore GM, Sizemore ST. The small G-protein RalA promotes progression and metastasis of triple-negative breast cancer. Breast Cancer Res. 2021 Jun 12;23(1):65. doi: 10.1186/s13058-021-01438-3. PMID: 34118960; PMCID: PMC8196523.
In vitro protocol:
1. Thies KA, Cole MW, Schafer RE, Spehar JM, Richardson DS, Steck SA, Das M, Lian AW, Ray A, Shakya R, Knoblaugh SE, Timmers CD, Ostrowski MC, Chakravarti A, Sizemore GM, Sizemore ST. The small G-protein RalA promotes progression and metastasis of triple-negative breast cancer. Breast Cancer Res. 2021 Jun 12;23(1):65. doi: 10.1186/s13058-021-01438-3. PMID: 34118960; PMCID: PMC8196523.
In vivo protocol:
1. Thies KA, Cole MW, Schafer RE, Spehar JM, Richardson DS, Steck SA, Das M, Lian AW, Ray A, Shakya R, Knoblaugh SE, Timmers CD, Ostrowski MC, Chakravarti A, Sizemore GM, Sizemore ST. The small G-protein RalA promotes progression and metastasis of triple-negative breast cancer. Breast Cancer Res. 2021 Jun 12;23(1):65. doi: 10.1186/s13058-021-01438-3. PMID: 34118960; PMCID: PMC8196523.
1: Yan C, Liu D, Li L, Wempe MF, Guin S, Khanna M, Meier J, Hoffman B, Owens C, Wysoczynski CL, Nitz MD, Knabe WE, Ahmed M, Brautigan DL, Paschal BM, Schwartz MA, Jones DN, Ross D, Meroueh SO, Theodorescu D. Discovery and characterization of small molecules that target the GTPase Ral. Nature. 2014 Nov 20;515(7527):443-7. doi: 10.1038/nature13713. Epub 2014 Sep 14. PubMed PMID: 25219851; PubMed Central PMCID: PMC4351747.
